Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CKS1B | P61024 | 1/20 | 0.49 |
| ▸ | SKP1 | P63208 | 1/20 | 0.49 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12205269 | 0.88 | GPR119 (0.56) | GPR119MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL24990142 | 0.86 | GPR119 (0.62) | GPR119MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL20311204 | 0.84 | GPR119 (0.57) | GPR119MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL31111540 | 0.84 | GPR119 (0.57) | GPR119MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL11359349 | 0.83 | GPR119 (0.53) | GPR119MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL594813 | 0.83 | GPR119 (0.80) | GPR119MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL1686074 | 0.83 | GPR119 (0.52) | GPR119MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL23839598 | 0.83 | GPR119 (0.52) | GPR119MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL32129014 | 0.83 | GPR119 (0.52) | GPR119MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL12225090 | 0.83 | GPR119 (0.52) | GPR119MAPTALDH1A1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| EP-3091008-B1 | KINASE INHIBITOR AND USE THEREOF | XUANZHU PHARMA CO LTD (CN) | 2018-06-27 | — | — | EP | disclosed |
| US-9949976-B2 | Kinase inhibitor and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-20180000819-A1 | KINASE INHIBITOR AND USE THEREOF | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2018-01-04 | — | — | US | disclosed |
| US-9796701-B2 | Kinase inhibitor and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-10-24 | — | — | US | disclosed |
| US-9796701-B2 | Kinase inhibitor and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-10-24 | — | — | US | disclosed |
| US-20160332989-A1 | Kinase Inhibitor And Use Thereof | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2016-11-17 | — | — | US | disclosed |
| US-20160332989-A1 | Kinase Inhibitor And Use Thereof | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2016-11-17 | — | — | US | disclosed |
| EP-3091008-A1 | KINASE INHIBITOR AND USE THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2016-11-09 | — | — | EP | disclosed |
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| CN-102015700-B | Antibacterial condensed thiazoles | BIOTA EUROPE LTD | 2014-12-03 | — | — | CN | disclosed |
| EP-2523664-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| WO-2011088192-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088192-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| CN-100448875-C | Substituted 1-piperazinoylpiperidine derivatives, their preparation and therapeutic use | SANOFI AVENTIS (FR) | 2009-01-07 | — | — | CN | disclosed |
| CN-1675203-A | Substituted 1-piperazinoylpiperidine derivatives, their preparation and therapeutic use | SANOFI AVENTIS (FR) | 2005-09-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | GPR119 136/4885MAPT 4392/4885ALDH1A1 3647/4885 |
| US-20160332989-A1 | Kinase Inhibitor And Use Thereof | CDK4, CDK6, CDK3 | GPR119 2215/4885MAPT 1491/4885ALDH1A1 2078/4885 |
| US-20180000819-A1 | KINASE INHIBITOR AND USE THEREOF | CDK4, CDK6, CDK3 | GPR119 2215/4885MAPT 1491/4885ALDH1A1 2078/4885 |
| US-20120289495-A1 | COMPOUNDS AND METHODS | XDH, CCNY, TOP2B | GPR119 1966/4885MAPT 4489/4885ALDH1A1 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.